IOL Chemicals Reports 9.8% Revenue Growth and 19.5% EBITDA Jump in Q1 Aug 13, 2025
IOL Chemicals & Pharmaceuticals reported robust Q1 FY24 results with revenue up 9.8% to Rs. 552.00 crores, EBITDA rising 19.5% to Rs. 69.50 crores, and PAT growing 14.4% to Rs. 34.00 crores. The company's new Paracetamol plant has begun exports to Europe, operating at 34% capacity. Export revenue comprises 25% of total sales, with plans to increase to 40%. The company received REACH registration for Acetic Anhydride in EU markets and is setting up Unit 9B for Minoxidil production. IOL Chemicals maintains its guidance of 14-15% EBITDA margins and 10% revenue growth for the full year, aiming for Rs. 2,000.00 crores in revenue from Ibuprofen and non-Ibuprofen segments within two years.
IOL Chemicals Unveils Strategic Expansion Plan Amid Strong Q1 Performance Aug 07, 2025
IOL Chemicals and Pharmaceuticals Reports Strong Q1 Performance, Plans UK Subsidiary and Minoxidil Production Aug 07, 2025
IOL Chemicals Secures EU REACH Registration for Acetic Anhydride Jun 13, 2025
IOL Chemicals: Q4 Net Profit Rises 13.7%, Margins Expand May 16, 2025
More news about IOL Chemicals & Pharmaceuticals
24Mar 25
IOL Chemicals and Pharma Boosts Production Capacity with New Paracetamol Unit and Clopidogrel Expansion
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has significantly expanded its production capabilities. The company launched a new Paracetamol production unit with a capacity of 10,800 MTPA, increasing total capacity to 14,400 MTPA. IOLCP also expanded its Clopidogrel Bisulphate manufacturing capacity from 180 MTPA to 240 MTPA. The Paracetamol expansion cost Rs 155.51 crore, while the Clopidogrel expansion required Rs 7.87 crore, both funded through internal accruals. The new Paracetamol unit includes backward integration with in-house production of key intermediates.